• Aprogen Biologics’ board on Oct. 8, 2026 resolved to extend collateral provided for its controlling shareholder Aprogen.
• Collateral supports KRW 41.5 billion of borrowings from Korea Eximbank, secured by the Osong plant land, buildings, equipment.
• Collateral amount set at KRW 63 billion, equal to 22.7% of consolidated equity at fiscal 2025 year-end.
• Collateral term runs from Oct. 19, 2026 to Apr. 19, 2027; total outstanding third-party collateral balance stands at KRW 72 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aprogen Biologics Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008800455), on October 08, 2026, and is solely responsible for the information contained therein.